| Nov 14 |
Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
|
| Nov 14 |
EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
|
| Nov 13 |
Adial Pharmaceuticals reports Q3 results
|
| Nov 13 |
Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 5 |
Adial Pharmaceuticals appoints Vinay Shah as CFO
|
| Nov 5 |
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
|
| Oct 23 |
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
|
| Oct 17 |
Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment
|
| Oct 17 |
EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate
|
| Oct 15 |
Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery
|
